<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021250</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2713</org_study_id>
    <nct_id>NCT05021250</nct_id>
  </id_info>
  <brief_title>SBRT With DIBH for HCC After TACE and Lipiodol Marking</brief_title>
  <official_title>Stereotactic Body Radiation Therapy With Deep Inspiration Breath Hold for Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization and Lipiodol Marking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic Body Radiation Therapy (SBRT) for hepatocellular carcinoma (HCC) with radical&#xD;
      dose achieved similar results with radiofrequency ablation (RF) and radical surgery,&#xD;
      according to previous studies. For tumors near great blood vessels or with a diameter more&#xD;
      than 2cm, SBRT performs even better than RF. In current clinical practice of SBRT for small&#xD;
      HCC, registration is achieved by planting metal markers near the tumor, which has several&#xD;
      disadvantages: 1. the operation is invasive, increase the risk of bleeding in patients with&#xD;
      cirrhosis; 2. the operation is of no therapeutic value; 3. metal markers can only be planted&#xD;
      outside the tumor to avoid transplantation, which compromises the accuracy of registration&#xD;
      via CBCT. This study aims to adopt a new method of registration, transcatheter arterial&#xD;
      chemoembolization (TACE) and lipiodol marking, to analyze the recognition and clarity of&#xD;
      lipiodol on CBCT images, set-up errors and treatment efficacy. Therefore to provide data to&#xD;
      support TACE and lipiodol marking over metal marker planting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH which was registrated with lipiodol.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recognition of lipiodol marking</measure>
    <time_frame>During the radiotherapy</time_frame>
    <description>Judged by 2 technicians and 1 physician on CBCT images. High recognition is concluded when all three consider it easily registered. Moderate recognition is concluded when two consider it easily registered. Poor recognition is concluded when one or none consider it easily registered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months after radiotherapy</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completion rate of treatment model</measure>
    <time_frame>1 months after TACE</time_frame>
    <description>Including the success rate of lipiodol deposition at 1 months after TACE and completion of SBRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCR</measure>
    <time_frame>12 months and 24 months after radiotherapy</time_frame>
    <description>Local control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months and 24 months after radiotherapy</time_frame>
    <description>Progress free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Frequency of treatment associated adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Lipiodol marking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lipiodol marking</intervention_name>
    <description>HCC patients treated with TACE and the tumor marked with lipiodol.</description>
    <arm_group_label>Lipiodol marking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinically or pathologically confirmed hepatocellular carcinoma.&#xD;
&#xD;
          2. ECOG 0-1.&#xD;
&#xD;
          3. BCLC C&#xD;
&#xD;
          4. Liver-GTV &gt;700ml; intrahepatic metastasis allowed but only one tumor is to be treated&#xD;
             with SBRT and others stable for more than 3 months; distant metastasis allowed but&#xD;
             stable for more than 6 months.&#xD;
&#xD;
          5. Expected gastric/duodenum/small intestine Dmax 25-35Gy; colon Dmax 28-38Gy.&#xD;
             Prescription dose 40Gy/5-10f.&#xD;
&#xD;
          6. DIBH training prior to SBRT to achieve 36 seconds breath hold.&#xD;
&#xD;
          7. Life expectancy &gt; 3 months.&#xD;
&#xD;
          8. Child-Pugh A5, A6 or B7.&#xD;
&#xD;
          9. Liver function: ALT within 1.5 times of upper limit; ALT within 0.5 times of upper&#xD;
             limit and AST within 6 times of upper limit, excluding cardiac infarction; ALT within&#xD;
             0.5-1.5 times of upper limit and AST within 1.5 times of upper limit&#xD;
&#xD;
         10. Normal ECG, without severe cardiac dysfunction&#xD;
&#xD;
         11. Kidney function: CRE, BUN within 1.5 times of upper limit.&#xD;
&#xD;
         12. CBC: Hb≥80g/L，ANC≥1.0×109 /L，PLT≥40×109 /L&#xD;
&#xD;
         13. Without hemorrhagic tendency.&#xD;
&#xD;
         14. Voluntarily participate in this trial and sign consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants of other clinical trials.&#xD;
&#xD;
          2. History of abdomen radiation therapy or liver transplantation.&#xD;
&#xD;
          3. History of severe cardiovascular, kidney or liver disease.&#xD;
&#xD;
          4. Pregnancy or lactation.&#xD;
&#xD;
          5. Suspected or confirmed of drug or alcohol abuse.&#xD;
&#xD;
          6. History of severe mental or neurological disease, compromising the ability to consent&#xD;
             and/or AE diagnosis.&#xD;
&#xD;
          7. Allergic to lipiodol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center/Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Chen</last_name>
    <phone>8610-87788223</phone>
    <email>cbchinese@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bo Chen</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Chen, MD</last_name>
      <phone>008613240000876</phone>
      <email>chenboo@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Bo Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huiying Zeng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liming Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Bo Chen</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma, TACE, SBRT, DIBH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

